Your Partners in Unlocking New Possibilities. Meet Our Leadership Team at CPHI Frankfurt at Booth No. 5.0C84.
Book a Meeting
Your Partners in Unlocking New Possibilities. Meet Our Leadership Team at CPHI Frankfurt at Booth No. 5.0C84.
Book a Meeting
.png)
In the race to bring new therapies to market, active pharmaceutical ingredient (API) development is often where timelines are made or lost. Efficient synthesis, scalability, and regulatory readiness all hinge on one critical step: identifying the most effective route of synthesis.
Oct 16, 2025
.png)
Antibody-Drug Conjugates (ADCs) have rapidly emerged as one of the most promising therapeutic classes in pharmaceuticals, particularly in oncology. By combining the targeting power of monoclonal antibodies (mAbs) with the potency of cytotoxic payloads, ADCs offer precision treatment options with reduced off-target effects.
Oct 13, 2025
.png)
Peptides are short chains of amino acids that play a natural role in many biological processes. In recent years, they have become an increasingly important class of therapeutics due to their specificity, versatility, and low toxicity. As a result, peptide APIs are now at the center of modern drug discovery and development.
Oct 01, 2025
.png)
Drug discovery and development involve multiple interconnected steps, including identifying promising candidates, developing formulations, conducting clinical research, seeking regulatory approvals, and scaling-up manufacturing.
Sep 26, 2025
-1.png)
Antibody-Drug Conjugates (ADCs) are rapidly gaining prominence in oncology and targeted therapeutics because they deliver highly potent drugs directly to diseased cells while minimizing collateral damage to healthy tissues.
Sep 22, 2025
-1.png)
-1.png)
.png)
.png)
.png)
.png)
-1.png)
.png)
.png)
.png)
